期刊
ATHEROSCLEROSIS
卷 231, 期 1, 页码 95-106出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2013.08.027
关键词
Peroxisome proliferator-activated receptor delta; Cardiovascular disease; Risk factors; Mouse models; Agonist; Single nucleotide polymorphism
资金
- Swedish Research Council
- Swedish Heart-Lung Foundation
- Karolinska Institutet Funds
- King Gustaf V and Queen Victoria's Foundation of Freemason
Recent reports have shown that peroxisome proliferator-activated receptor delta (PPARD) plays an important role in different vascular processes suggesting that PPARD is a significant modulator of cardiovascular disease. This review will focus on PPARD in relation to cardiovascular risk factors based on cell, animal and human data. Mouse studies suggest that PPARD is an important metabolic modulator that may have implications for cardiovascular disease (CVD). Specific human PPARD gene variants show no clear association with CVD but interactions between variants and lifestyle factors might influence disease risk. During recent years, development of specific and potent PPARD agonists has also made it possible to study the effects of PPARD activation in humans. PPARD agonists seem to exert beneficial effects on dyslipidemia and insulin-resistant syndromes but safety issues have been raised due to the role that PPARD plays in cell proliferation. Thus, large long term outcome as well as detailed safety and tolerability studies are needed to evaluate whether PPARD agonists could be used to treat CVD in humans. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据